Diclofenac-Viola 1% Gel, 40 g

Made to order
$54.00

Ingredients

Active ingredient: diclofenac sodium;

  • 1 g of gel contains 10 mg of diclofenac sodium;

inactive ingredients: propylene glycol, 96% ethanol, macrogol 400, carbomer 980, purified water, methyl parahydroxybenzoate (E 218).

Dosage Form

Gel.

Main physical and chemical properties: a homogeneous, colorless, transparent, or slightly opalescent gel.

Pharmacotherapeutic group

Topical agents for joint and muscle pain. Topical nonsteroidal anti-inflammatory drugs. Diclofenac.

ATC code M02A A15.

Pharmacological Properties

Pharmacodynamics.

Diclofenac is a nonsteroidal anti-inflammatory drug with pronounced antirheumatic, analgesic, anti-inflammatory, and antipyretic effects. Its primary mechanism of action is the inhibition of prostaglandin biosynthesis.

In cases of inflammation caused by trauma or rheumatic diseases, Diclofenac-Viola reduces pain and tissue swelling and shortens the recovery period for damaged joints, ligaments, tendons, and muscles. Clinical data have shown that Diclofenac-Viola reduces acute pain as early as 1 hour after the initial application. 94% of patients responded to Diclofenac-Viola after 2 days of treatment, compared to 8% who responded to a placebo. Relief from pain and functional impairments was achieved after 4 days of treatment with Diclofenac-Viola. Thanks to its water-alcohol base, the medication also provides a local anesthetic and cooling effect.

Pharmacokinetics.

The amount of diclofenac absorbed through the skin is proportional to the area of application and depends on both the total dose of the drug applied and the degree of skin hydration. After topical application of 2.5 g of Diclofenac-Viola to a 500 cm² area of skin, the absorption rate of diclofenac is approximately 6%. The use of an occlusive dressing for 10 hours results in a threefold increase in diclofenac absorption.

After applying Diclofenac-Viola to the skin over the wrist and knee joints, diclofenac is detected in the blood plasma (where its maximum concentration is approximately 100 times lower than after oral administration), in the synovial membrane and synovial fluid. The protein binding of diclofenac is 99.7%.

Diclofenac accumulates in the skin, which acts as a reservoir from which the substance is gradually released into the surrounding tissues. From there, diclofenac primarily reaches deeper inflamed tissues, such as joints, where it continues to act and is detected at concentrations up to 20 times higher than in blood plasma.

Diclofenac is metabolized primarily by hydroxylation to form several phenolic derivatives, two of which are pharmacologically active, but to a much lesser extent than diclofenac.

Diclofenac and its metabolites are excreted primarily in the urine. The total systemic plasma clearance of diclofenac is 263 ± 56 mL/min, and the terminal half-life averages 1–3 hours.

In patients with renal or hepatic insufficiency, the metabolism and excretion of diclofenac are not altered.

Clinical Characteristics.

Indications

Topical treatment of pain and inflammation of joints, muscles, ligaments, and tendons of rheumatic or traumatic origin.

Contraindications for Diclofenac-Viola

Hypersensitivity to diclofenac or to any other components of the drug. A history of bronchial asthma attacks, angioedema, urticaria, or acute rhinitis caused by the use of acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs; the third trimester of pregnancy.

Interactions with other medications and other types of interactions.

Since systemic absorption of diclofenac following topical application is very low, the likelihood of interactions is very low.

Special Considerations for Use

Use with caution when administered concomitantly with oral nonsteroidal anti-inflammatory drugs.

The likelihood of systemic side effects (which occur with systemic forms of diclofenac) should be considered when applying the medication to larger areas of the skin or for a longer duration than recommended. In such cases, the drug should be used with caution in patients with hepatic, renal, or cardiac insufficiency, as well as in those with active peptic ulcer disease.

Diclofenac-Viola should be applied only to intact, undamaged areas of the skin, avoiding contact with inflamed, injured, or infected skin. Avoid contact with the eyes and mucous membranes. Do not swallow the medication.

If any skin rashes appear, treatment with the medication should be discontinued. Diclofenac-Viola should not be applied under an airtight occlusive dressing, but its use under a non-occlusive dressing is permitted.

Diclofenac-Viola contains propylene glycol, which may cause mild localized skin irritation.

Due to the possibility of photosensitivity, avoid direct sunlight and visits to tanning beds during treatment and for 2 weeks after discontinuing treatment.

Use During Pregnancy or Breastfeeding.

Clinical experience with use in pregnant women is limited. Like other nonsteroidal anti-inflammatory drugs, Diclofenac-Viola is contraindicated during the third trimester of pregnancy due to the potential for weakened labor, impaired fetal renal function leading to oligohydramnios and/or cardiopulmonary toxicity with premature closure of the ductus arteriosus and pulmonary hypertension. Use of the drug during the first two trimesters of pregnancy is permitted only if the expected benefit outweighs the potential risk to the fetus. However, women planning pregnancy and those during the first two trimesters of pregnancy are advised to reduce the dosage to the lowest possible level and shorten the duration of treatment.

It is unknown whether diclofenac is excreted into breast milk when applied topically; therefore, the use of Diclofenac-Viola during breastfeeding is permitted only if the expected benefit outweighs the potential risk to the infant. If there are compelling reasons to use the medication during breastfeeding, it should not be applied to the breasts or large areas of skin, and it should not be used in larger amounts or for a longer duration than recommended.

There are no data on the effect of diclofenac on human fertility when applied topically.

Effect on reaction time when driving or operating machinery.

No effect.

Dosage and Administration of Diclofenac-Viola

This medication is intended for external use only.

For adults and children 14 years of age and older, apply Diclofenac-Viola 3–4 times daily, gently rubbing it into the skin at the site of pain. The amount of medication used depends on the size of the affected area (for example, 2–4 g—about the size of a cherry or a walnut—is sufficient to cover an area of 400–800 cm²).

After applying the medication, wash your hands, unless the area being treated is your hands.

The duration of therapy depends on the nature of the condition and the effectiveness of treatment.

The product should not be used for more than 14 consecutive days for soft tissue injuries or rheumatism, or for more than 21 days for arthritis-related pain, unless otherwise recommended by a doctor.

Consult a doctor if symptoms do not improve or worsen after 7 days of treatment.

Elderly patients may use the standard adult dose of the medication.

Children.

Diclofenac-Viola is not recommended for use in children under 14 years of age. If the medication is used in children over 14 years of age for longer than 7 days, or if symptoms worsen, consult a doctor.

Overdose

Overdose is unlikely due to the low absorption of diclofenac into the systemic circulation when applied topically. However, side effects similar to those that occur with an overdose of diclofenac-containing tablets are possible if the product is accidentally swallowed. In this case, it should be noted that 1 tube of the product (40 g or 100 g) contains the equivalent of 0.4 g or 1 g of diclofenac sodium, respectively.

In case of accidental ingestion, the stomach should be emptied immediately and an adsorbent administered. Symptomatic treatment is indicated, using therapeutic measures applied for the treatment of poisoning with nonsteroidal anti-inflammatory drugs.

Adverse Reactions to Diclofenac-Viola

The following adverse reactions have been observed with the drug Diclofenac-Viola.

Infections and infestations

Rare (<1/10,000): pustular rash.

Immune system

Rare (<1/10,000): hypersensitivity reactions (including urticaria), angioedema.

Respiratory system

Rare (<1/10,000): bronchial asthma.

Skin and connective tissue disorders

Common (≥1/100; <1/10): rash, itching, eczema, erythema, dermatitis, including contact dermatitis.

Isolated cases (≥1/10,000; <1/1,000): bullous dermatitis.

Rare (<1/10,000): photosensitivity reactions.

If side effects occur, discontinue treatment and consult a doctor.

Shelf life

2 years.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C; do not freeze. Keep out of reach of children.

Packaging

40 g or 100 g in tubes; 1 tube per pack or without a pack.

Pharmacy Dispensing Category

Over-the-counter.